Antibiotics

Effectiveness of post-exposure prophylaxis (PEP) with doxycycline for chlamydia and syphilis comes with increase in resistant gonorrhea.

Fluoroquinolones are broadly active and convenient, but black box warnings and resistance concerns have reshaped when and how clinicians should use them.

A 5-day course of nitrofurantoin was found superior to single-dose fosfomycin for uncomplicated UTI in women, prompting investigators to recommend choosing efficacy over convenience.

Meera Mehta, PharmD, says OPAT programs should move away from a “one-size-fits-all” monitoring model and instead tailor laboratory follow-ups based on patient risk factors, antimicrobial toxicity, and quality-of-life considerations.

SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, explains how the new partnership between SIDP and MAD-ID brings together organizations with shared leadership and values to create a more accessible, collaborative meeting space for infectious diseases pharmacists and related specialties.

In the second installment of our interview with Andrew Handel, MD, he provides insights on Lyme Disease treatment in the pediatric population.

Stephanie Spivack, MD, discusses an upcoming healthcare provider symposium that will provide education around treating novel infections for patients with substance use disorder (SUD).

With spring here and tick bites on the rise, Andrew Handel, MD, provides tips on prevention as well as when to consider medical care for a bite.

The growing incidence of resistant Gram-negative infections in hospitals is being fueled by evolving resistance mechanisms, antibiotic overuse, and the rapid global spread of mobile genetic elements. Mariana Castanheira, PhD, FIDSA, FAAM, chief scientific officer at JMI Laboratories, discusses this topic and an agent with utility against pathogens carrying Metallo-beta-lactamases (MBLs).

Mortality rates from treatment-resistant gram-negative infections remain high despite increased use of newer antibiotics and corresponding susceptibility testing.

New real-world data from the CIRCE study underscore cefiderocol’s potential in treating metallo-beta-lactamase–producing Enterobacterales infections, particularly among critically ill and immunocompromised patients with limited therapeutic options. Christine Slover, PharmD, offers some insights around the study and these infections.

A major international study reveals that World Health Organization-recommended first-line antibiotics are effective in only one in four neonatal sepsis infections in low- and middle-income countries, underscoring the growing threat of antimicrobial resistance.

AMR Action Fund CEO Henry Skinner, PhD, MBE, provides insights around the legislation including its implementation challenges which may be slowing its path to passage despite bipartisan support in Congress as well as growing recognition of the global antimicrobial resistance crisis.

In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones.

In the second episode of this short series, Akhila Kosaraju, MD, talks about how Phare Bio and Basilea Pharmaceuticals are partnering to develop antimicrobials taking them from AI molecules to clinical trials.

A new study shows that strain-level surveillance of Staphylococcus aureus in NICUs can identify hidden transmission pathways and enable targeted interventions to reduce serious infections in vulnerable newborns.

Akhila Kosaraju, MD, provides insights around how AI is moving towards an accelerated pace of antimicrobial development in hopes of getting molecules into clinical trials and approved much faster than the current paradigm.

Shionogi has been awarded a major US government contract to scale domestic manufacturing and expand the use of its antibiotic cefiderocol to combat antimicrobial resistance and high-priority biothreat pathogens.

The inaugural MAD-ID and SIDP 2026 meeting aims to provide new infectious diseases education offerings, dynamic speakers, and strong networking opportunities for younger clinicians. SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, offers some insights around the upcoming event.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI.

A new meta-analysis finds alarming increases in colistin resistance among Acinetobacter baumannii and Pseudomonas aeruginosa across Africa, threatening the effectiveness of one of the last-resort antibiotics.

The World Health Organization has released 3 new target product profiles aimed at guiding the development of urgently needed antibiotics for severe drug-resistant infections, including multidrug-resistant gram-negative infections, resistant gram-positive infections in vulnerable patients, and bacterial meningitis.

Peptilogics has enrolled the first patient in its RETAIN trial evaluating PLG0206, a first-in-class anti-biofilm therapy designed to treat prosthetic joint infections.

Emerging preclinical, compassionate-use, and randomized trial data suggest phage-antibiotic combinations may benefit select patients with multidrug-resistant infections, yet critical gaps in standardization and evidence remain.

In 2025, the Infectious Diseases Society of America published the first part of an update to the clinical practice guideline on the diagnosis and management of GAS pharyngitis. Here is an overview of the risk assessment and antibiotic treatment of GAS pharyngitis.